Breast Cancer, Psychology, Social
Conditions
Keywords
Psychological intervention Alcohol, Tobacco consumption, Substance use, Health risk behavior, Oncology setting, Women, Supportive care
Brief summary
Despite scientific, clinical and political incentives, alcohol and/or tobacco screening and brief intervention (SBI) services are poorly implemented in oncology settings. Motivational brief interventions are recognized as particularly effective in changing health behaviors, especially consumption behaviors. The motivational approach is more and more used in primary care setting but still few studies explore its effectiveness with breast cancer patients. This study aims to compare two intervention arms : educational advices intervention (EAI) versus brief motivational intervention (BMI) for alcohol and/or tobacco consumption in breast cancer women, during their treatment. In this pilot prospective randomized trial, various psychological and behavioral, variables are measured (alcohol and tobacco consumption, distress, anxiety and depressive disorders, quality of life, motivation for change, empowerment) before the brief intervention, and after 3 and 6 month.
Detailed description
Context : It is now well documented that alcohol and tobacco reduce the effectiveness of a treatment, increase the side effects, favor the recurrence and/or secondary cancers and affects the quality of life of patients treated for cancer, including breast cancer. The announcement of the disease could create a window of opportunity for change in lifestyle for patients. The 2014-2019 French Cancer Plan emphasizes the need for the implementation of prevention and risk reduction related to alcohol and tobacco. A screening, brief motivational and referral to treatment program, specifically dedicated to oncology can be public health approach aiming to reduce the harmful consequences of substance misuse and improving the prognosis and quality of life of consumers at risk. Main objective : Evaluate effectiveness of a brief motivational intervention for alcohol and/or tobacco in short (3 month) and medium (6 month) terms in breast cancer patients, in a prospective randomized pilot study. Secondary objectives : * Determine the behavioral and psychopathological specific characteristics of the patient linked to change process and maintain. * Define a brief intervention for alcohol/tobacco consumption model adapted and integrated to patient treated for cancer according to psychosocial factors highlighted. The investigators will seek to highlight the benefit of a motivational brief intervention versus standardized educational advice. The specificity of these interventions is to be integrated in an interview integrating a systematic screening of the emotional distress of the patient, of these concerns as well as of his perceived need for aids. Method : This is a randomized clinical trial comparing two interventions. The trial includes 200 primary breast cancer patients with a positive AUDIT-C score and/or are tobacco consumers, randomly placed in two groups : G1 : Motivational Intervention group (N = 100) : Participants in the intervention group benefit a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention. G2 : Educational advises group (N = 100) : Participants in this group benefit of brief educational advises (10 minutes interview maximum), and received a pamphlet on the health effects of alcohol and tobacco consumption. For obvious ethical reasons, the investigators selected an intervention in the form of advice concerning the effects of the product and the submission of specific documentation (criteria not retained in the context of the brief intervention model). It did not seem possible to evaluate patients without offering them the possibility of a low threshold intervention. Detailed scripts for each modality of intervention are realized. Measurement : Three sets of measurements are taken at baseline, 3-month and 6 month follow-up. Primary Outcome measures: Clinically significant reduction (beneficial to health) of risk behaviours (alcohol and/or tobacco consumption) : * Concerning subjects with only alcohol consumption at baseline : The intervention will be considered effective at 3 months if an individual decrease of 20% in the AUDIT score is observed at 3 months compared to the value collected at baseline; The intervention will be considered effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline. * The same applies to subjects with only tobacco consumption at baseline: The intervention will be considered effective at 3 months if an individual decrease of 20% in the number of cigarettes consumed per day is observed at 3 months compared to the value collected at baseline; The intervention will be judged effective at 6 months if this 20% reduction is maintained at 6 months, still in relation to the value collected at baseline. * Finally, with regard to women with both alcohol and tobacco use at baseline : The intervention will be considered effective if at least one of the two scores (AUDIT or number of cigarettes consumed per day) has decreased by 20% at 3 months (maintained at 6 months) compared to the value collected at baseline, with no increase in the other score. Secondary outcome measures : * Individual reduction of around 20% in average daily consumption of alcohol and/or tobacco (calculated on the basis of patients' consumption schedules) between inclusion and the first follow-up at 3 months, and maintenance of this success at the second follow-up at 6 months (with no increase in other consumption if the subject has both alcohol and tobacco consumption at inclusion); * Description of the variables relating to the consumption of alcohol, tobacco, the current medico-psychological situation, psychological distress, anxio-depressive symptomatology, willingness to change alcohol and/or tobacco consumption habits; * Improved quality of life in the experimental intervention arm compared to the standard intervention arm Study procedure : SCREENING-PRE-INCLUSION: Screening of distress and alcohol/tobacco consumptions is realized when the patients arrive in the oncology department for their chemotherapy treatment, by a research assistant-psychologist. Researchers propose to eligible patients to participate to the study. This first contact permits to check the absence of non-inclusion criteria; to ensure the informed consent of the person (an information and consent note will be given to him) and according to these elements, to define the provisional timetable for participation in the research. T0 - INCLUSION AND RANDOMIZATION The research assistant retrieves the signed consent, ensuring a time available to return if necessary and carries out the research interview/assessment. The randomization is realized following this interview. INTERVENTION: Brief intervention (G1 : Brief motivational intervention or G2 : educational advices) are conducted by the research assistant-psychologist, at the Institut Bergonié or by telephone if needed. T1: MONITORING - FOLLOW-UP(3 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary. T2: MONITORING - FOLLOW-UP (6 months) Assessments are repeated, when the patient comes at the Institut Bergonié, by telephone if necessary. Randomization procedure : The randomization procedure is done via the TENALEA server, managed by the Epidemiological and Clinical Research Unit (UREC) of the Bergonié Institute. Expected results : Highlighting: * The efficacy of motivational brief intervention on alcohol and tobacco consumption in patients treated for breast cancer ; versus educational advices intervention. * Psychosocial risk factors involved in maintaining problematic consumption or in the rapid relapse of tobacco/alcohol consumption.
Interventions
Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
Sponsors
Study design
Eligibility
Inclusion criteria
: * women with primary breast cancer, without ongoing support for substance use. * An AUDIT-C score \>1 or more than one cigarette smoked per day. * Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index \>70).
Exclusion criteria
: * Patients who currently use substances for which a second-line care is already committed. * Patients with a Karnofsky index \<70.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | 3 months | Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence). |
| Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | 3 months and 6 months | Individual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months. Success depends on tobacco consumption at 3 months and 6 months. AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Per Current Treatments at Baseline | Baseline | — |
| Number of Patients Per Current Treatments at 3 Months | 3 months | — |
| Number of Patients Per Current Treatments at 6 Months | 6 months | — |
| Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline, 3 months and 6 months | Ongoing psychotropic treatment(s) at baseline, 3 months and 6 months. |
| Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline, 3 months and 6 months | Current monitoring with regard to behaviour/emotional state |
| Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Baseline | Type of professional followed for behaviour/emotional state at baseline |
| Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | 3 months | Type of professional followed for behaviour/emotional state at 3 months |
| Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | 6 months | Type of professional followed for behaviour/emotional state at 6 months |
| AUDIT Score at Baseline, 3 Months, and 6 Months | Baseline, 3 months, 6 months | Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 (No alcohol consumption) to 12 (alcohol dependence). Consumption profiles can be derived from this. Higher scores indicate a worse outcome: alcohol dependence. |
| Currently, How Many Cigarettes Per Day do You Smoke on Average? | Baseline, 3 months and 6 months | — |
| Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | 3 months | Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion). |
| Type of Consumption of Electronic Cigarettes | Baseline, 3 months and 6 months | — |
| Fagerström Score | Baseline, 3 months, 6 months | Fagerström test assesses tobacco consumption and makes it possible to describe patterns of tobacco addiction. Its score ranges from 0 (non-addiction to smoking) to 10 (strong or very strong dependence on tobacco). |
| MADRS Score | Baseline, 3 months, 6 months | MADRS (Montgomery-Åsberg Depression Rating Scale) assesses the severity of depression in patients with mood disorders. Its score ranges from 0 (normothymic) to 60 (depression). |
| Score of Hamilton | Baseline, 3 months and 6 months | Hamilton test assesses symptoms of anxiety. Its score ranges from 0 to 56. The higher the score is, the more severe the depression is. |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) | 3 months | QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health. |
| HEIQ Score | Baseline, 3 months, 6 months | HEIQ (Health Education Impact Questionnaire) assesses the concept of empowerment (health-promoting behaviours, commitment, social integration, etc.). Its scores range from 0 to 160. Higher scores mean a better health-related empowerment . |
| Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | Baseline, 3 months and 6 months | This score ranges from 0 to 140. The questionnaire consists of 14 questions on motivation to change alcohol/tobacco consumption habits, each with a response scale ranging from 0 (probably not) to 10 (probably). For each question, a sub-score ranges from 0 to 10 is given and then a total score of motivation to change consumption habits is calculated by adding up all the answers to the 14 items. The higher the score is, greater the patient's willingness to change his or her alcohol/tobacco consumption. |
| Satisfaction Questionnaire | 3 months | — |
| On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 3 months | Satisfaction score ranges from 1 to 10. Low scores indicate less satisfaction. |
| Number of Patients Who Consume Electronic Cigarettes | Baseline, 3 months and 6 months | — |
| Number of Patients With Decreased Alcohol and/or Tobacco Consumption | 3 months and 6 months | Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months and a continuation of this reduction at the second follow-up at 6 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion). Success depends on alcohol and tobacco level consumption at 3 months and 6 months. |
Countries
France
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm 1 Arm 1: Motivational Intervention group
Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention. | 51 |
| Arm 2 Arm 2 : Educational advises group
Educational advises group: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption. | 53 |
| Total | 104 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Refusal to continue | 3 | 4 |
| Overall Study | Withdrawal by Subject | 9 | 3 |
Baseline characteristics
| Characteristic | Arm 2 | Total | Arm 1 |
|---|---|---|---|
| Age, Continuous | 48.0 years STANDARD_DEVIATION 8.9 | 48.4 years STANDARD_DEVIATION 9.6 | 48.8 years STANDARD_DEVIATION 10.4 |
| AUDIT Score (patient) | 2.9 scores on a scale STANDARD_DEVIATION 2 | 3.2 scores on a scale STANDARD_DEVIATION 3.3 | 3.4 scores on a scale STANDARD_DEVIATION 4.2 |
| Current family situation Divorced | 5 Participants | 12 Participants | 7 Participants |
| Current family situation In a couple | 16 Participants | 32 Participants | 16 Participants |
| Current family situation Married | 25 Participants | 46 Participants | 21 Participants |
| Current family situation Single | 6 Participants | 10 Participants | 4 Participants |
| Current family situation Widowed | 1 Participants | 4 Participants | 3 Participants |
| Currently, how many cigarettes per day does the patient's spouse smoke on average? | 10.8 Cigarettes STANDARD_DEVIATION 6.9 | 11.1 Cigarettes STANDARD_DEVIATION 7.5 | 11.5 Cigarettes STANDARD_DEVIATION 8.1 |
| Currently, how many cigarettes per day do you smoke on average? | 10.8 Cigarettes per day STANDARD_DEVIATION 6.9 | 11.1 Cigarettes per day STANDARD_DEVIATION 7.5 | 11.5 Cigarettes per day STANDARD_DEVIATION 8.1 |
| Current monitoring with regard to behaviour/emotional state Missing | 1 Participants | 1 Participants | 0 Participants |
| Current monitoring with regard to behaviour/emotional state No | 36 Participants | 74 Participants | 38 Participants |
| Current monitoring with regard to behaviour/emotional state Yes | 16 Participants | 29 Participants | 13 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Alcohol No | 15 Participants | 34 Participants | 19 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Alcohol Yes | 1 Participants | 4 Participants | 3 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Cannabis No | 16 Participants | 37 Participants | 21 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Cannabis Yes | 0 Participants | 1 Participants | 1 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Other No | 16 Participants | 38 Participants | 22 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Other Yes | 0 Participants | 0 Participants | 0 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Tobacco No | 1 Participants | 5 Participants | 4 Participants |
| DSM5 - Current Life - Substance-related or addictive disorders Tobacco Yes | 15 Participants | 33 Participants | 18 Participants |
| DSM5 - Substance-related or addictive disorders (current life) No | 37 Participants | 66 Participants | 29 Participants |
| DSM5 - Substance-related or addictive disorders (current life) Yes | 16 Participants | 38 Participants | 22 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Anxiety disorders Missing | 0 Participants | 0 Participants | 0 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Anxiety disorders No | 43 Participants | 88 Participants | 45 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Anxiety disorders Yes | 10 Participants | 16 Participants | 6 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Bipolar and related disorders Missing | 0 Participants | 0 Participants | 0 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Bipolar and related disorders No | 51 Participants | 102 Participants | 51 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Bipolar and related disorders Yes | 2 Participants | 2 Participants | 0 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Depressive disorders Missing | 0 Participants | 0 Participants | 0 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Depressive disorders No | 48 Participants | 95 Participants | 47 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Depressive disorders Yes | 5 Participants | 9 Participants | 4 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Disorders related to trauma or stressors Missing | 0 Participants | 1 Participants | 1 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Disorders related to trauma or stressors No | 50 Participants | 97 Participants | 47 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) Disorders related to trauma or stressors Yes | 3 Participants | 6 Participants | 3 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) OCD and related Missing | 0 Participants | 1 Participants | 1 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) OCD and related No | 52 Participants | 102 Participants | 50 Participants |
| DSM5 - Substance-related or addictive disorders (Current Life) OCD and related Yes | 1 Participants | 1 Participants | 0 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Alcohol No | 34 Participants | 70 Participants | 36 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Alcohol Yes | 0 Participants | 4 Participants | 4 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Cannabis No | 34 Participants | 73 Participants | 39 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Cannabis Yes | 0 Participants | 1 Participants | 1 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Other No | 34 Participants | 73 Participants | 39 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Other Yes | 0 Participants | 1 Participants | 1 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Tobacco No | 0 Participants | 5 Participants | 5 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Tobacco Yes | 34 Participants | 69 Participants | 35 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) No | 19 Participants | 30 Participants | 11 Participants |
| DSM5 - Substance-related or addictive disorders (whole life) Yes | 34 Participants | 74 Participants | 40 Participants |
| DSM5 - Whole Life Anxiety disorders No | 39 Participants | 77 Participants | 38 Participants |
| DSM5 - Whole Life Anxiety disorders Yes | 14 Participants | 27 Participants | 13 Participants |
| DSM5 - Whole Life Bipolar and related disorders No | 51 Participants | 102 Participants | 51 Participants |
| DSM5 - Whole Life Bipolar and related disorders Yes | 2 Participants | 2 Participants | 0 Participants |
| DSM5 - Whole Life Depressive disorders No | 28 Participants | 63 Participants | 35 Participants |
| DSM5 - Whole Life Depressive disorders Yes | 25 Participants | 41 Participants | 16 Participants |
| DSM5 - Whole Life Disorders related to trauma or stressors No | 40 Participants | 80 Participants | 40 Participants |
| DSM5 - Whole Life Disorders related to trauma or stressors Yes | 13 Participants | 24 Participants | 11 Participants |
| DSM5 - Whole Life OCD and related No | 51 Participants | 101 Participants | 50 Participants |
| DSM5 - Whole Life OCD and related Yes | 2 Participants | 3 Participants | 1 Participants |
| DSM5 - Whole Life Substance-related or Addictive No | 19 Participants | 30 Participants | 11 Participants |
| DSM5 - Whole Life Substance-related or Addictive Yes | 34 Participants | 74 Participants | 40 Participants |
| Electronic cigarettes No | 24 Participants | 49 Participants | 25 Participants |
| Electronic cigarettes Yes | 3 Participants | 5 Participants | 2 Participants |
| Fagerström score | 3.4 scores on a scale STANDARD_DEVIATION 2.6 | 3.4 scores on a scale STANDARD_DEVIATION 2.6 | 3.4 scores on a scale STANDARD_DEVIATION 2.6 |
| HEIQ (health Education Impact Questionnaire) score | 118.6 scores on a scale STANDARD_DEVIATION 12.6 | 118.6 scores on a scale STANDARD_DEVIATION 12.1 | 118.6 scores on a scale STANDARD_DEVIATION 11.7 |
| In the past year, how often did the patient's spouse smoke? At least once a week | 1 Participants | 4 Participants | 3 Participants |
| In the past year, how often did the patient's spouse smoke? Every day or almost every day | 17 Participants | 33 Participants | 16 Participants |
| In the past year, how often did the patient's spouse smoke? Never | 24 Participants | 44 Participants | 20 Participants |
| Level of education Below high school diploma | 10 Participants | 20 Participants | 10 Participants |
| Level of education Higher than bachelor's degree | 18 Participants | 35 Participants | 17 Participants |
| Level of education High school diploma to bachelor's degree (included) | 24 Participants | 46 Participants | 22 Participants |
| Level of education No diploma | 1 Participants | 3 Participants | 2 Participants |
| MADRS Score (Categorical variable) Depression Medium | 4 Participants | 10 Participants | 6 Participants |
| MADRS Score (Categorical variable) Mild depression | 21 Participants | 36 Participants | 15 Participants |
| MADRS Score (Categorical variable) Normothymic | 28 Participants | 58 Participants | 30 Participants |
| MADRS Score (Quantitative variable) | 7.9 scores on a scale STANDARD_DEVIATION 6.3 | 7.9 scores on a scale STANDARD_DEVIATION 6.9 | 7.9 scores on a scale STANDARD_DEVIATION 7.6 |
| Number of children | 1.8 Child STANDARD_DEVIATION 1 | 1.8 Child STANDARD_DEVIATION 1 | 1.8 Child STANDARD_DEVIATION 0.9 |
| Ongoing psychotropic treatment(s) No | 35 Participants | 70 Participants | 35 Participants |
| Ongoing psychotropic treatment(s) Yes | 18 Participants | 34 Participants | 16 Participants |
| Past treatment(s) Chemotherapy No | 27 Participants | 49 Participants | 22 Participants |
| Past treatment(s) Chemotherapy Yes | 26 Participants | 55 Participants | 29 Participants |
| Past treatment(s) Hormonotherapy No | 51 Participants | 98 Participants | 47 Participants |
| Past treatment(s) Hormonotherapy Yes | 2 Participants | 6 Participants | 4 Participants |
| Past treatment(s) Radiotherapy No | 50 Participants | 99 Participants | 49 Participants |
| Past treatment(s) Radiotherapy Yes | 3 Participants | 5 Participants | 2 Participants |
| Past treatment(s) Surgery No | 31 Participants | 67 Participants | 36 Participants |
| Past treatment(s) Surgery Yes | 22 Participants | 37 Participants | 15 Participants |
| Past treatment(s) Without treatment No | 38 Participants | 79 Participants | 41 Participants |
| Past treatment(s) Without treatment Yes | 15 Participants | 25 Participants | 10 Participants |
| Profession Artisans, merchants and company director | 2 Participants | 2 Participants | 0 Participants |
| Profession Company's exécutives and higher intellectual profession | 16 Participants | 27 Participants | 11 Participants |
| Profession Economically inactive | 6 Participants | 15 Participants | 9 Participants |
| Profession Employees | 25 Participants | 46 Participants | 21 Participants |
| Profession Farmer-operators | 0 Participants | 0 Participants | 0 Participants |
| Profession Intermediate professions | 1 Participants | 6 Participants | 5 Participants |
| Profession Labor | 2 Participants | 4 Participants | 2 Participants |
| Profession Pensioners | 1 Participants | 4 Participants | 3 Participants |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Score Audit categorical variable (Patient) Harmful consumption | 6 Participants | 9 Participants | 3 Participants |
| Score Audit categorical variable (Patient) Low-risk consumption | 44 Participants | 77 Participants | 33 Participants |
| Score Audit categorical variable (Patient) No consumption | 3 Participants | 14 Participants | 11 Participants |
| Score Audit categorical variable (Patient) Probable dependency | 0 Participants | 4 Participants | 4 Participants |
| Score of Hamilton | 5.6 scores on a scale STANDARD_DEVIATION 7 | 5.6 scores on a scale STANDARD_DEVIATION 6.5 | 5.6 scores on a scale STANDARD_DEVIATION 6.1 |
| Sex: Female, Male Female | 53 Participants | 104 Participants | 51 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
| Spouse's AUDIT-C score | 3.4 scores on a scale STANDARD_DEVIATION 1.9 | 3.5 scores on a scale STANDARD_DEVIATION 2.2 | 3.6 scores on a scale STANDARD_DEVIATION 2.6 |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Appetite loss | 17.0 Standardized scores on a scale | 16.2 Standardized scores on a scale | 15.3 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Cognitive functioning | 77.8 Standardized scores on a scale | 78.8 Standardized scores on a scale | 79.9 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Constipation | 15.7 Standardized scores on a scale | 15.0 Standardized scores on a scale | 14.3 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Diarrhoea | 18.3 Standardized scores on a scale | 14.3 Standardized scores on a scale | 10.2 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Dyspnoea | 20.9 Standardized scores on a scale | 22.7 Standardized scores on a scale | 24.5 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Emotional functioning | 76.5 Standardized scores on a scale | 75.7 Standardized scores on a scale | 74.9 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Fatigue | 42 Standardized scores on a scale | 43.7 Standardized scores on a scale | 45.4 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Financial difficulties | 25.5 Standardized scores on a scale | 23.2 Standardized scores on a scale | 20.8 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Global health status/QoL (revised) | 65.4 Standardized scores on a scale | 63.6 Standardized scores on a scale | 61.6 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Insomnia | 34.0 Standardized scores on a scale | 33.7 Standardized scores on a scale | 33.3 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Nausea and vomiting | 7.8 Standardized scores on a scale | 8.2 Standardized scores on a scale | 8.5 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Pain | 23.9 Standardized scores on a scale | 25.3 Standardized scores on a scale | 26.9 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Physical functioning | 83.5 Standardized scores on a scale | 82.2 Standardized scores on a scale | 80.8 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Role functioning | 80.1 Standardized scores on a scale | 80.7 Standardized scores on a scale | 81.3 Standardized scores on a scale |
| Standardised Quality of Life Scores (EORTC - QLQ-C30) Social functioning | 74.8 Standardized scores on a scale | 75.5 Standardized scores on a scale | 76.2 Standardized scores on a scale |
| Tumor extension stage Missing | 3 Participants | 7 Participants | 4 Participants |
| Tumor extension stage T0 | 2 Participants | 3 Participants | 1 Participants |
| Tumor extension stage T1 | 11 Participants | 20 Participants | 9 Participants |
| Tumor extension stage T2 | 21 Participants | 44 Participants | 23 Participants |
| Tumor extension stage T3 | 13 Participants | 26 Participants | 13 Participants |
| Tumor extension stage T4 | 3 Participants | 4 Participants | 1 Participants |
| Type of cancer Canal carcinoma in situ | 4 Participants | 4 Participants | 0 Participants |
| Type of cancer Ductal carcinoma infiltrant | 42 Participants | 90 Participants | 48 Participants |
| Type of cancer Other | 7 Participants | 10 Participants | 3 Participants |
| Type of consumption of electronic cigarettes With nicotine | 3 Participants | 4 Participants | 1 Participants |
| Type of consumption of electronic cigarettes Without nicotine | 0 Participants | 1 Participants | 1 Participants |
| Type of professional Health professional specialising in tobaccoology and addiction No | 15 Participants | 28 Participants | 13 Participants |
| Type of professional Health professional specialising in tobaccoology and addiction Yes | 1 Participants | 1 Participants | 0 Participants |
| Type of professional Other professional No | 16 Participants | 28 Participants | 12 Participants |
| Type of professional Other professional Yes | 0 Participants | 1 Participants | 1 Participants |
| Type of professional Psychiatrist No | 14 Participants | 25 Participants | 11 Participants |
| Type of professional Psychiatrist Yes | 2 Participants | 4 Participants | 2 Participants |
| Type of professional Psychologist No | 3 Participants | 6 Participants | 3 Participants |
| Type of professional Psychologist Yes | 13 Participants | 23 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months
Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Time frame: 3 months
Population: Only patients with available data at 3 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Success | 23 Participants |
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Success not maintained | 18 Participants |
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Missing | 7 Participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Success | 19 Participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Success not maintained | 29 Participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months | Missing | 5 Participants |
Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months
Individual decrease of 20% in the AUDIT score observed at 3 months compared to the value collected at baseline and maintained at 6 months. Success depends on tobacco consumption at 3 months and 6 months. AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 to 28. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).
Time frame: 3 months and 6 months
Population: Only patients with available data at 3 months and 6 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Success not maintained | 1 participants |
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Success | 17 participants |
| Arm 1 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Missing | 5 participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Success | 14 participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Success not maintained | 1 participants |
| Arm 2 | Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months and Maintained at 6 Months | Missing | 4 participants |
AUDIT Score at Baseline, 3 Months, and 6 Months
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score ranges from 0 (No alcohol consumption) to 12 (alcohol dependence). Consumption profiles can be derived from this. Higher scores indicate a worse outcome: alcohol dependence.
Time frame: Baseline, 3 months, 6 months
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | AUDIT Score at Baseline, 3 Months, and 6 Months | Baseline | 3.4 score on a scale | Standard Deviation 4.2 |
| Arm 1 | AUDIT Score at Baseline, 3 Months, and 6 Months | 3 months | 3.6 score on a scale | Standard Deviation 5.4 |
| Arm 1 | AUDIT Score at Baseline, 3 Months, and 6 Months | 6 months | 3.0 score on a scale | Standard Deviation 4.9 |
| Arm 2 | AUDIT Score at Baseline, 3 Months, and 6 Months | Baseline | 2.9 score on a scale | Standard Deviation 2 |
| Arm 2 | AUDIT Score at Baseline, 3 Months, and 6 Months | 3 months | 2.6 score on a scale | Standard Deviation 1.8 |
| Arm 2 | AUDIT Score at Baseline, 3 Months, and 6 Months | 6 months | 2.7 score on a scale | Standard Deviation 2.6 |
Currently, How Many Cigarettes Per Day do You Smoke on Average?
Time frame: Baseline, 3 months and 6 months
Population: Only smokers who have completed form at baseline, 3 months and 6 months.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | Baseline | 11.5 Cigarettes per day | Standard Deviation 8.1 |
| Arm 1 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | 3 months | 9.3 Cigarettes per day | Standard Deviation 6.1 |
| Arm 1 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | 6 months | 9.1 Cigarettes per day | Standard Deviation 6.9 |
| Arm 2 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | Baseline | 10.8 Cigarettes per day | Standard Deviation 6.9 |
| Arm 2 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | 3 months | 10.4 Cigarettes per day | Standard Deviation 7 |
| Arm 2 | Currently, How Many Cigarettes Per Day do You Smoke on Average? | 6 months | 11.0 Cigarettes per day | Standard Deviation 8.7 |
Fagerström Score
Fagerström test assesses tobacco consumption and makes it possible to describe patterns of tobacco addiction. Its score ranges from 0 (non-addiction to smoking) to 10 (strong or very strong dependence on tobacco).
Time frame: Baseline, 3 months, 6 months
Population: In smokers only (N=54 smokers at baseline)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Fagerström Score | Baseline | 3.4 score on a scale | Standard Error 2.6 |
| Arm 1 | Fagerström Score | 6 months | 3.0 score on a scale | Standard Error 2.3 |
| Arm 1 | Fagerström Score | 3 months | 3.7 score on a scale | Standard Error 2.5 |
| Arm 2 | Fagerström Score | 6 months | 3.7 score on a scale | Standard Error 2.7 |
| Arm 2 | Fagerström Score | Baseline | 3.4 score on a scale | Standard Error 2.6 |
| Arm 2 | Fagerström Score | 3 months | 3.8 score on a scale | Standard Error 2.1 |
HEIQ Score
HEIQ (Health Education Impact Questionnaire) assesses the concept of empowerment (health-promoting behaviours, commitment, social integration, etc.). Its scores range from 0 to 160. Higher scores mean a better health-related empowerment .
Time frame: Baseline, 3 months, 6 months
Population: Patients with available score at baseline or 3 months or 6 months.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | HEIQ Score | Baseline | 119 scores on a scale | Standard Deviation 11.7 |
| Arm 1 | HEIQ Score | 3 months | 114 scores on a scale | Standard Deviation 11.2 |
| Arm 1 | HEIQ Score | 6 months | 118 scores on a scale | Standard Deviation 13.4 |
| Arm 2 | HEIQ Score | Baseline | 119 scores on a scale | Standard Deviation 12.6 |
| Arm 2 | HEIQ Score | 3 months | 117.5 scores on a scale | Standard Deviation 12.5 |
| Arm 2 | HEIQ Score | 6 months | 120 scores on a scale | Standard Deviation 12.5 |
MADRS Score
MADRS (Montgomery-Åsberg Depression Rating Scale) assesses the severity of depression in patients with mood disorders. Its score ranges from 0 (normothymic) to 60 (depression).
Time frame: Baseline, 3 months, 6 months
Population: Eligible and assessable patients who have completed the MADRS questionnaire at baseline, 3 months and 6 months. For this questionnaire, there were no missing data at each time point (baseline, 3 months and 6 months).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | MADRS Score | Baseline | 7.9 score on a scale | Standard Error 7.6 |
| Arm 1 | MADRS Score | 3 months | 8.5 score on a scale | Standard Error 7.2 |
| Arm 1 | MADRS Score | 6 months | 7.9 score on a scale | Standard Error 7.9 |
| Arm 2 | MADRS Score | Baseline | 7.9 score on a scale | Standard Error 6.3 |
| Arm 2 | MADRS Score | 3 months | 6.3 score on a scale | Standard Error 5.8 |
| Arm 2 | MADRS Score | 6 months | 4.8 score on a scale | Standard Error 5.2 |
Motivation Score to Change Consumption Habits (Alcohol/Tobacco)
This score ranges from 0 to 140. The questionnaire consists of 14 questions on motivation to change alcohol/tobacco consumption habits, each with a response scale ranging from 0 (probably not) to 10 (probably). For each question, a sub-score ranges from 0 to 10 is given and then a total score of motivation to change consumption habits is calculated by adding up all the answers to the 14 items. The higher the score is, greater the patient's willingness to change his or her alcohol/tobacco consumption.
Time frame: Baseline, 3 months and 6 months
Population: Patients with available score.
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | 6 months | 120 scores on a scale | Standard Deviation 19.6 |
| Arm 1 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | Baseline | 121 scores on a scale | Standard Deviation 22.9 |
| Arm 1 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | 3 months | 129 scores on a scale | Standard Deviation 29 |
| Arm 2 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | 3 months | 126 scores on a scale | Standard Deviation 38.5 |
| Arm 2 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | 6 months | 126 scores on a scale | Standard Deviation 31.7 |
| Arm 2 | Motivation Score to Change Consumption Habits (Alcohol/Tobacco) | Baseline | 117.5 scores on a scale | Standard Deviation 32 |
Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months
Type of professional followed for behaviour/emotional state at 6 months
Time frame: 6 months
Population: Patients with current monitoring with regard to behaviour/emotional state
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychiatrist | No | 5 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychiatrist | Yes | 3 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Health professional specialising in tobaccoology and addiction | No | 7 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Health professional specialising in tobaccoology and addiction | Yes | 1 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Other professional | No | 8 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Other professional | Yes | 0 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychologist | No | 1 Participants |
| Arm 1 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychologist | Yes | 7 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychologist | Yes | 3 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychiatrist | No | 2 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Other professional | No | 6 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychiatrist | Yes | 4 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Psychologist | No | 3 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Health professional specialising in tobaccoology and addiction | No | 6 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Other professional | Yes | 0 Participants |
| Arm 2 | Number of Patients by Type of Professional Monitored for Behaviour/Emotional State at 6 Months | Health professional specialising in tobaccoology and addiction | Yes | 0 Participants |
Number of Patients Per Current Treatments at 3 Months
Time frame: 3 months
Population: Only patients with available data at 3 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | No | 32 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | No treatment | Missing | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | Yes | 10 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | No treatment | No | 36 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | Missing | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | No treatment | Yes | 10 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | Missing | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Surgery | Missing | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | Yes | 14 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Surgery | No | 40 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | No | 33 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Surgery | Yes | 6 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | No | 36 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | Missing | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | Yes | 13 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | Missing | 4 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | No | 40 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Chemotherapy | Yes | 9 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | Missing | 4 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | No | 30 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Radiotherapy | Yes | 19 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | Missing | 4 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | No | 39 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Hormonotherapy | Yes | 10 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | No treatment | Missing | 4 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | No treatment | No | 36 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | No treatment | Yes | 13 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Surgery | Missing | 4 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Surgery | No | 47 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 3 Months | Surgery | Yes | 2 Participants |
Number of Patients Per Current Treatments at 6 Months
Time frame: 6 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | No | 46 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | Yes | 7 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Surgery | No | 49 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | Yes | 5 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | No | 35 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | Yes | 16 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | No treatment | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | No treatment | No | 42 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Surgery | Yes | 2 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | No treatment | Yes | 9 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | No | 44 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at 6 Months | Surgery | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | No treatment | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Surgery | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Surgery | No | 53 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Surgery | Yes | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | No | 47 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Chemotherapy | Yes | 6 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | No | 45 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Radiotherapy | Yes | 8 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | No | 28 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | Hormonotherapy | Yes | 25 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | No treatment | No | 43 Participants |
| Arm 2 | Number of Patients Per Current Treatments at 6 Months | No treatment | Yes | 10 Participants |
Number of Patients Per Current Treatments at Baseline
Time frame: Baseline
Population: Only patients with available data at baseline
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | Yes | 2 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | No treatment | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | No treatment | No | 51 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Surgery | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Surgery | No | 50 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Surgery | Yes | 1 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | No | 4 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | Yes | 47 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | No | 50 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | Yes | 1 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | Missing | 0 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | No | 49 Participants |
| Arm 1 | Number of Patients Per Current Treatments at Baseline | No treatment | Yes | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | No treatment | Yes | 1 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | Yes | 1 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | No | 2 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | No treatment | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | Yes | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | No treatment | No | 52 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | Yes | 51 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | No | 52 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Surgery | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Surgery | No | 52 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Hormonotherapy | Missing | 0 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Surgery | Yes | 1 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Radiotherapy | No | 53 Participants |
| Arm 2 | Number of Patients Per Current Treatments at Baseline | Chemotherapy | Missing | 0 Participants |
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months
Type of professional followed for behaviour/emotional state at 3 months
Time frame: 3 months
Population: Patients with current monitoring with regard to behaviour/emotional state
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychiatrist | No | 13 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychiatrist | Yes | 2 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychologist | No | 4 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychologist | Yes | 11 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Health professional specialising in tobaccoology and addiction | No | 15 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Health professional specialising in tobaccoology and addiction | Yes | 0 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Other professional | No | 13 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Other professional | Yes | 2 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Other professional | Yes | 0 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychiatrist | No | 5 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Health professional specialising in tobaccoology and addiction | No | 8 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Other professional | No | 8 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychologist | No | 3 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Health professional specialising in tobaccoology and addiction | Yes | 0 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychologist | Yes | 5 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at 3 Months | Psychiatrist | Yes | 3 Participants |
Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline
Type of professional followed for behaviour/emotional state at baseline
Time frame: Baseline
Population: Patients with current monitoring with regard to behaviour/emotional state
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Other professional | No | 12 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychiatrist | Yes | 2 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychologist | Yes | 10 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Health professional specialising in tobaccoology and addiction | No | 13 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychologist | No | 3 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychiatrist | No | 11 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Other professional | Yes | 1 Participants |
| Arm 1 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Health professional specialising in tobaccoology and addiction | Yes | 0 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Other professional | Yes | 0 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Health professional specialising in tobaccoology and addiction | Yes | 1 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychologist | No | 3 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychologist | Yes | 13 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychiatrist | No | 14 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Psychiatrist | Yes | 2 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Health professional specialising in tobaccoology and addiction | No | 15 Participants |
| Arm 2 | Number of Patients Who by Type of Professional Monitored for Behaviour/Emotional State at Baseline | Other professional | No | 16 Participants |
Number of Patients Who Consume Electronic Cigarettes
Time frame: Baseline, 3 months and 6 months
Population: Only smokers at baseline (N=54), 3 months (N=37) and 6 months (N=30).
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | Baseline | No | 25 Participants |
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | Baseline | Yes | 2 Participants |
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | 3 months | No | 17 Participants |
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | 3 months | Yes | 3 Participants |
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | 6 months | No | 15 Participants |
| Arm 1 | Number of Patients Who Consume Electronic Cigarettes | 6 months | Yes | 2 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | 6 months | No | 12 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | Baseline | No | 24 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | 3 months | Yes | 1 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | Baseline | Yes | 3 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | 6 months | Yes | 1 Participants |
| Arm 2 | Number of Patients Who Consume Electronic Cigarettes | 3 months | No | 16 Participants |
Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months
Ongoing psychotropic treatment(s) at baseline, 3 months and 6 months.
Time frame: Baseline, 3 months and 6 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | Missing | 5 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | No | 34 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | Yes | 16 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | Yes | 12 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | No | 29 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | Yes | 8 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | Missing | 0 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | Missing | 14 Participants |
| Arm 1 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | No | 35 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | Missing | 9 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | No | 35 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | Yes | 18 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | Missing | 4 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | No | 30 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | Baseline | Missing | 0 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | No | 35 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 3 months | Yes | 14 Participants |
| Arm 2 | Number of Patients Who Continued Psychotropic Treatment(s) at Baseline, 3 Months and 6 Months | 6 months | Yes | 14 Participants |
Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State
Current monitoring with regard to behaviour/emotional state
Time frame: Baseline, 3 months and 6 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | Missing | 0 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | Yes | 15 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | No | 38 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | No | 31 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | Yes | 13 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | No | 29 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | Missing | 14 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | Yes | 8 Participants |
| Arm 1 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | Missing | 5 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | Yes | 6 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | Missing | 4 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | No | 41 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 3 months | Yes | 8 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | Missing | 10 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | Missing | 1 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | No | 36 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | 6 months | No | 37 Participants |
| Arm 2 | Number of Patients Who Has Current Monitoring With Regard to Behaviour/Emotional State | Baseline | Yes | 16 Participants |
Number of Patients With Decreased Alcohol and/or Tobacco Consumption
Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months and a continuation of this reduction at the second follow-up at 6 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion). Success depends on alcohol and tobacco level consumption at 3 months and 6 months.
Time frame: 3 months and 6 months
Population: Patients with tobacco or alcohol consumption at baseline and data available at 3 months and 6 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm 1 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Success | 6 Participants |
| Arm 1 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Failure | 2 Participants |
| Arm 1 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Missing | 4 Participants |
| Arm 2 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Success | 6 Participants |
| Arm 2 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Failure | 2 Participants |
| Arm 2 | Number of Patients With Decreased Alcohol and/or Tobacco Consumption | Missing | 7 Participants |
Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption
Individual reduction of around 20% in the average daily consumption of alcohol and/or tobacco (calculated on the basis of consumption schedules) between inclusion and the first follow-up at 3 months (with no increase in the other consumption if the subject has both alcohol and tobacco consumption at inclusion).
Time frame: 3 months
Population: Patients with tobacco or alcohol consumption at baseline and available data at 3 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm 1 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Success | 12 Participants |
| Arm 1 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Failure | 22 Participants |
| Arm 1 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Missing | 14 Participants |
| Arm 2 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Success | 15 Participants |
| Arm 2 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Failure | 26 Participants |
| Arm 2 | Number of Patients With Individual Decreased of Alcohol and/or Tobacco Consumption | Missing | 12 Participants |
On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute?
Satisfaction score ranges from 1 to 10. Low scores indicate less satisfaction.
Time frame: 3 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 7 | 0 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | Missing | 15 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 8 | 11 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 5 | 3 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 9 | 8 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 6 | 2 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 10 | 12 Participants |
| Arm 1 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 3 | 0 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 10 | 11 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | Missing | 6 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 3 | 1 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 6 | 4 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 7 | 3 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 8 | 17 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 9 | 6 Participants |
| Arm 2 | On a Scale of 1 to 10 How Would You Rate Your Overall Satisfaction With Having Benefited From a Brief Intervention at the Bergonié Institute? | 5 | 5 Participants |
Satisfaction Questionnaire
Time frame: 3 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Missing | 14 Participants |
| Arm 1 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | No | 1 Participants |
| Arm 1 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Yes | 30 Participants |
| Arm 1 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Don't know | 6 Participants |
| Arm 1 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Missing | 14 Participants |
| Arm 1 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | No | 1 Participants |
| Arm 1 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Yes | 33 Participants |
| Arm 1 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Don't know | 3 Participants |
| Arm 1 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Missing | 16 Participants |
| Arm 1 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | No | 29 Participants |
| Arm 1 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Yes | 6 Participants |
| Arm 1 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Don't know | 0 Participants |
| Arm 2 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Yes | 6 Participants |
| Arm 2 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Missing | 6 Participants |
| Arm 2 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Yes | 40 Participants |
| Arm 2 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | No | 2 Participants |
| Arm 2 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | No | 41 Participants |
| Arm 2 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Yes | 42 Participants |
| Arm 2 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Don't know | 5 Participants |
| Arm 2 | Satisfaction Questionnaire | Do you think it would be important to ask cancer patients about their consumption behaviour? | Don't know | 3 Participants |
| Arm 2 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Don't know | 0 Participants |
| Arm 2 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | Missing | 7 Participants |
| Arm 2 | Satisfaction Questionnaire | Would you have liked the questions on consumption to have been asked at another time? | Missing | 6 Participants |
| Arm 2 | Satisfaction Questionnaire | Would it be useful to ask cancer patients about their alcohol/tobacco consumption behaviour | No | 1 Participants |
Score of Hamilton
Hamilton test assesses symptoms of anxiety. Its score ranges from 0 to 56. The higher the score is, the more severe the depression is.
Time frame: Baseline, 3 months and 6 months
Population: Eligible and assessable patients who have completed the Hamilton questionnaire at baseline, 3 months and 6 months. For this questionnaire, there were no missing data at each time point (baseline, 3 months and 6 months).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Score of Hamilton | Baseline | 5.6 score on a scale | Standard Deviation 6.1 |
| Arm 1 | Score of Hamilton | 3 months | 4.5 score on a scale | Standard Deviation 5.3 |
| Arm 1 | Score of Hamilton | 6 months | 4.4 score on a scale | Standard Deviation 6 |
| Arm 2 | Score of Hamilton | Baseline | 5.6 score on a scale | Standard Deviation 7 |
| Arm 2 | Score of Hamilton | 3 months | 3.5 score on a scale | Standard Deviation 4.1 |
| Arm 2 | Score of Hamilton | 6 months | 2.6 score on a scale | Standard Deviation 3.3 |
Standardised Quality of Life Scores (EORTC - QLQ-C30)
QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
Time frame: 3 months
Population: Participants who completed at least one item of the questionnaire. Note that some participants may not have completed the 30 items of the questionnaires, which explains why the number of participants differs for the different items of the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Role functioning | 84.6 scores on a scale | Standard Deviation 18 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Emotional functioning | 67.9 scores on a scale | Standard Deviation 27 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Cognitive functioning | 75.8 scores on a scale | Standard Deviation 27.1 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Nausea and vomiting | 5.3 scores on a scale | Standard Deviation 12.6 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Financial difficulties | 23.8 scores on a scale | Standard Deviation 32.3 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Physical functioning | 81.0 scores on a scale | Standard Deviation 16.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Social functioning | 70.6 scores on a scale | Standard Deviation 29.9 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Fatigue | 42.0 scores on a scale | Standard Deviation 26.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Pain | 26.4 scores on a scale | Standard Deviation 25.3 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Dyspnoea | 15.4 scores on a scale | Standard Deviation 25.9 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Insomnia | 42.3 scores on a scale | Standard Deviation 32.5 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Appetite loss | 14.6 scores on a scale | Standard Deviation 22.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Constipation | 8.9 scores on a scale | Standard Deviation 18.3 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Diarrhoea | 4.9 scores on a scale | Standard Deviation 11.9 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Global health status/QoL | 61.1 scores on a scale | Standard Deviation 17.9 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Social functioning | 78.7 scores on a scale | Standard Deviation 24.3 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Role functioning | 89.0 scores on a scale | Standard Deviation 17.8 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Insomnia | 37.6 scores on a scale | Standard Deviation 30.8 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Fatigue | 39.0 scores on a scale | Standard Deviation 21.1 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Constipation | 5.7 scores on a scale | Standard Deviation 12.7 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Nausea and vomiting | 3.9 scores on a scale | Standard Deviation 7.9 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Dyspnoea | 27.0 scores on a scale | Standard Deviation 19.2 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Pain | 28.7 scores on a scale | Standard Deviation 21.3 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Financial difficulties | 21.3 scores on a scale | Standard Deviation 28.2 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Global health status/QoL | 64.2 scores on a scale | Standard Deviation 18.4 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Appetite loss | 12.1 scores on a scale | Standard Deviation 18.9 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Physical functioning | 82.1 scores on a scale | Standard Deviation 18.1 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Emotional functioning | 76.3 scores on a scale | Standard Deviation 20.2 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Cognitive functioning | 81.6 scores on a scale | Standard Deviation 18.5 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Diarrhoea | 8.0 scores on a scale | Standard Deviation 22.4 |
Standardised Quality of Life Scores (EORTC - QLQ-C30)
QLQ-C30 questionnaire (EORTC) assesses quality of life across 15 dimensions : * 5 functional dimensions : Physical functioning, Role functioning, Emotional, Cognitive functioning, Social functioning; * 9 symptomatic dimensions: Fatigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, Appetite loss, Diarrhoea, Financial difficulties; * 1 global health dimension: Global health status/QoL Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
Time frame: 6 months
Population: Participants who completed at least one item of the questionnaire. Note that some participants may not have completed the 30 items of the questionnaires, which explains why the number of participants differs for the different items of the questionnaires.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Cognitive functioning | 72.5 scores on a scale | Standard Deviation 30.2 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Pain | 27.0 scores on a scale | Standard Deviation 27 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Diarrhoea | 5.4 scores on a scale | Standard Deviation 18.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Dyspnoea | 17.1 scores on a scale | Standard Deviation 24.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Emotional functioning | 62.6 scores on a scale | Standard Deviation 28.7 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Insomnia | 48.6 scores on a scale | Standard Deviation 33 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Role functioning | 81.5 scores on a scale | Standard Deviation 24.1 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Appetite loss | 13.5 scores on a scale | Standard Deviation 24.2 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Fatigue | 44.1 scores on a scale | Standard Deviation 23.6 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Constipation | 20.7 scores on a scale | Standard Deviation 31.8 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Social functioning | 70.7 scores on a scale | Standard Deviation 33.4 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Financial difficulties | 23.1 scores on a scale | Standard Deviation 33.6 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Nausea and vomiting | 7.2 scores on a scale | Standard Deviation 20.6 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Global health status/QoL | 58.3 scores on a scale | Standard Deviation 20.7 |
| Arm 1 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Physical functioning | 80.2 scores on a scale | Standard Deviation 18.5 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Global health status/QoL | 63.6 scores on a scale | Standard Deviation 20.6 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Physical functioning | 86.0 scores on a scale | Standard Deviation 16 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Role functioning | 88.2 scores on a scale | Standard Deviation 19.5 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Emotional functioning | 75.6 scores on a scale | Standard Deviation 18.2 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Cognitive functioning | 78.5 scores on a scale | Standard Deviation 21.8 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Social functioning | 81.7 scores on a scale | Standard Deviation 27.6 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Diarrhoea | 7.5 scores on a scale | Standard Deviation 16 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Fatigue | 31.4 scores on a scale | Standard Deviation 20.5 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Nausea and vomiting | 4.1 scores on a scale | Standard Deviation 12.2 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Pain | 26.8 scores on a scale | Standard Deviation 25.8 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Dyspnoea | 21.1 scores on a scale | Standard Deviation 27.6 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Insomnia | 37.4 scores on a scale | Standard Deviation 32.7 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Appetite loss | 3.3 scores on a scale | Standard Deviation 10 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Constipation | 9.8 scores on a scale | Standard Deviation 22.7 |
| Arm 2 | Standardised Quality of Life Scores (EORTC - QLQ-C30) | Financial difficulties | 22.8 scores on a scale | Standard Deviation 35.3 |
Type of Consumption of Electronic Cigarettes
Time frame: Baseline, 3 months and 6 months
Population: Patient with electronic cigarette use and who answered the form
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Arm 1 | Type of Consumption of Electronic Cigarettes | 6 months | With nicotine | 1 Participants |
| Arm 1 | Type of Consumption of Electronic Cigarettes | 6 months | Without nicotine | 1 Participants |
| Arm 1 | Type of Consumption of Electronic Cigarettes | Baseline | With nicotine | 1 Participants |
| Arm 1 | Type of Consumption of Electronic Cigarettes | Baseline | Without nicotine | 1 Participants |
| Arm 1 | Type of Consumption of Electronic Cigarettes | 3 months | With nicotine | 2 Participants |
| Arm 1 | Type of Consumption of Electronic Cigarettes | 3 months | Without nicotine | 1 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | 3 months | With nicotine | 1 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | 6 months | With nicotine | 1 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | Baseline | Without nicotine | 0 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | 6 months | Without nicotine | 0 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | 3 months | Without nicotine | 0 Participants |
| Arm 2 | Type of Consumption of Electronic Cigarettes | Baseline | With nicotine | 3 Participants |